A Lump After NeoFilera? The Insert Itself Gives a 1-to-14-Month Window

Look NeoFilera up and seven pages out of ten will tell you it carries a low risk of nodules. Round particles, even sizing, a smooth surface. All of that is true, and it is genuinely the direction the product was designed in.

The trouble is that you can feel something hard right now.

This article is not going to argue with that marketing line, because it is not answering the same question you have. Low risk describes a probability. You are holding an outcome. However low the number, it is 100% once it happens to you, and none of the decisions ahead of you get any easier for having read it.

NeoFilera (poly-D,L-lactic acid, PDLLA, nicknamed the "pong-pong needle" in Taiwanese clinics) has one advantage over most fillers here: its approved insert is unusually specific, including about when nodules can appear and what can be done about them. That document is approved by the health authority. It is not anyone's marketing copy, and it is not my opinion either.

So let's start there.

Key point: Patients are usually told that a quiet first few months means they are in the clear. That is not the window the approval document describes. A late lump is worth imaging rather than dismissing on timing alone.

First, confirm what you were actually injected with

Before we talk about the lump, confirm the material. This step gets skipped often, and it shapes every judgement that follows.

NeoFilera is a Taiwanese-made PDLLA collagen stimulator, licence number 008439 in the domestic-manufacture series. The character 製 in that number marks it as made in Taiwan rather than imported. Chief Biotech holds the licence, manufacturing is contracted to Shuo-Nuo Biotechnology in New Taipei, and the licence covers two presentations, S-100 and S-200.

It is often filed as a Korean PDLLA. The Korean MFDS register in fact has no entry for it. The impression probably comes from the fact that most PDLLA products reaching Taiwan are Korean.

Why split that hair? Because "both are PDLLA" does not mean the same object goes into your tissue. Bench work from a team at National Taipei University of Technology (Polymers 2026;18(1):84, PMID 41516868) measured four lactic-acid fillers side by side: AestheFill, Sculptra, NeoFilera and Juvelook. NeoFilera and AestheFill came out almost identical in particle size, 25.03 ± 4.86 microns against 24.98 ± 4.84, and opposite in surface texture, NeoFilera smooth and AestheFill wrinkled and rough. Reconstitution time was where they separated most: NeoFilera at 140.7 seconds was the fastest of the four, AestheFill at 966.3 seconds the slowest, with Sculptra at 250.0 and Juvelook at 450.7 in between.

Two things need saying so this is not over-read. First, the paper only describes AestheFill's reconstitution as dramatically longer; the roughly 6.9-fold figure is arithmetic on those numbers, not the authors' wording. Second, 966 seconds is not 966 seconds of quiet dissolving. The protocol was to leave the vial standing and, if the particles had not dissolved after 15 minutes, to vortex it until they did, so that number includes a forced step. The authors attribute the difference to manufacturing: AestheFill by solvent spray, NeoFilera most likely by emulsification.

The same study also measured osmolality, NeoFilera at 265.00 and AestheFill at 261.33 mOsm/kg, both below the physiological range of 275 to 295, which led the authors to recommend that both products' inserts carry a warning about post-injection discomfort or swelling. That finding does not flatter NeoFilera. It comes from the same paper as the numbers above, and quoting only the flattering half is not citing.

That second row deserves a note. The approval documents give the total weight per vial, 100mg for S-100 and 200mg for S-200, and never state how that weight divides between PDLLA and CMC (carboxymethylcellulose, a common gel carrier). The "150mg of PDLLA plus 50mg of CMC" figure in circulation is the 75:25 ratio from a marketing page, multiplied out. When you see a milligram figure quoted for this product, it is worth tracing where it came from.

The full material record is on the NeoFilera material page, so I will not repeat it here.

You can look this document up yourself

I know "the insert says" sounds like you have to take my word for it. So here is how to check, which takes about two minutes.

Taiwan's medical device licence data is public and searchable by product name or by the number 008439. The record shows the Chinese product name, the English name NEOFILERA Dermal Filler, Chief Biotech as licence holder, Shuo-Nuo Biotechnology as manufacturer, and S-100 and S-200 in the specification field.

Two things to watch while you are there.

Look at the prefix of the licence number, not just the six digits. The same six digits under a different series is a different licence: 製 is domestic manufacture, 輸 is import. While checking this, I found clinic treatment pages listing NeoFilera under the import series. The series is simply wrong there. It is a small thing, but it tells you that page was not checked against the record, which makes the rest of its numbers worth less.

The efficacy field for this product reads "see the approved Chinese labelling". So the public database does not carry its approved indication; the indication lives in the approved insert. Those two facts often get merged into "the authority doesn't list it, so there is no approved indication", which is a different claim. There is one. It is on another document.

The insert's own window: 1 to 14 months, sometimes two years

Now that document.

Under potential adverse reactions, it states that subcutaneous nodules may appear late, between 1 and 14 months after injection, and sometimes as late as two years. The same section notes that nodules forming after treatment, including visible nodules around the eyes, may come with inflammation or discolouration.

What that sentence does, practically, is turn time from a reason for dismissal back into a clue. A lump that surfaced fifteen months after the injection sits inside that window, not outside it.

What I see in clinic tends to go like this. The patient takes the lump back to the original clinic, is told the gap is too long and it must be something else, and then goes around dermatology, has it worked up as a cyst or a lymph node, and a few months pass. The lump is still there. The fibrosis around it is thicker.

That document will not make the diagnosis for you. It does at least mean you are not carrying the whole burden of proof for the sentence "this might be related to the injection".

Key point: Late does not mean unrelated. Looking once with ultrasound is more reliable than reasoning from the calendar, and faster.

Why it takes so long to surface

The difference between a collagen stimulator and hyaluronic acid is that the stimulator does not finish its work when the volume goes in.

PDLLA works by prompting your own tissue to build collagen, and that process runs in months. The carrier is absorbed first. The particles stay, and your body keeps responding to them. So the moment a problem appears need not sit anywhere near the day of the injection.

The patterns I see behind a late nodule:

• Particles placed too superficially or unevenly, clumping and then getting walled off by fibrous tissue
• An unusually strong personal collagen response, building more than anyone planned for
• Material sitting quietly until something amplifies the immune response: a local infection, an injury, sometimes just a bad cold

Those three look different on ultrasound and they call for different handling. Which is the reason to look before acting. The same hard lump under your finger can be clumped material, a fibrous capsule, or an inflammatory granuloma.

What are you actually feeling: roughness, a lump, swelling, or a granuloma

People often open with "I have a nodule", but something hard is not necessarily a nodule. Telling these apart matters, because they pull in different directions.

Roughness is a distribution problem. Your fingertip reads unevenness, a fine grainy quality, with nothing discrete to pinch. Usually particles placed a little too superficially or unevenly, and most obvious where skin is thin.

A lump can be located. You can find its edge, it stays in one place, you can hold it between your fingers. Mostly clumped material plus the fibrous tissue that has grown around it.

Swelling changes. Up today, down tomorrow, worse in the evening, or suddenly bigger after a cold, a bad night, or a vaccination. That pattern usually involves an immune response rather than material sitting in a heap.

A granuloma is a mass of tissue formed by a foreign-body reaction, often with recurring redness, warmth and tenderness, and it feels harder and more fixed than plain encapsulation. It needs different handling from the other three.

Those four have different imaging features. Which is why I am unwilling to decide from palpation alone: fingers read hard and soft, they do not read depth, plane, or whether a capsule has formed.

For how nodules sort by time of onset and which rung of treatment each calls for, the treatment ladder for PDLLA nodules covers it more fully, and that ladder applies to NeoFilera in the same way.

Early softening is not necessarily the problem

One situation is worth setting out first, because it turns up in clinic regularly and almost nobody is warned about it.

This class of product is a freeze-dried powder, reconstituted with fluid before injection. The approved insert gives S-100 4.0cc of diluent and S-200 8.0cc. Once that fluid is in, part of the fullness you see in the first few weeks is the fluid itself, and it gets absorbed. The collagen is a slower story that comes afterwards.

So noticing that some volume has gone at one or two months is an expected part of the process with this class of material. It is not a failure, and it is not a lump. What deserves attention is the opposite pattern: a spot that does not settle but keeps getting fuller and firmer, or whose shape drifts away from the tissue next to it.

I raise it because both changes arrive mixed together in how patients describe things. Separating them makes what you say at a follow-up much more precise, and makes it easier for your doctor to catch what matters.

What ultrasound is actually looking for here

I keep saying look before acting. Looking for what, specifically? Four things that change your decision.

Which plane the material sits in. The same lump in the superficial subcutis and deep down are different problems to handle, with different risks, and this also settles where an access point can be made.

How far it extends. What feels like one lump is often a continuous sheet on the image. Extent is what decides whether this is one session or several.

Whether there is a capsule, and how thick. This is what decides whether conservative handling still has a chance. With a thin capsule, drugs and physical release still have room. With a thick, complete one, more injections mostly buy time.

How close the vessels and nerves are. Around the eyes and temples especially, this decides whether anything can be done safely, and how far.

None of the four can be read with a fingertip. So in my practice ultrasound is not an add-on. It is the precondition for deciding whether to treat at all, and how.

Surgical removal is not the drastic option; it is on the label

Patients often open with an apology: "Am I overreacting, wanting it cut out?"

You are not. Where the approved insert for NeoFilera discusses managing nodules, what it says is this: if required, voluntary surgical removal of the nodule, or steroid treatment.

I quote that line often, because it closes an argument. Whether extraction is a legitimate route has already been answered inside the approval document. It does not need each clinic to have its own opinion about it. A patient asking for it is not asking for something unusual.

That said, "it can be removed" and "it was removed well" are two different things. Among the cases that reach me, the largest group is not people nobody has treated. It is people who had material taken out elsewhere, were left uneven, and came looking for help with that. So what we care about is never only whether it comes out. It is three things.

Cleanly, meaning the residue does not get left half-finished. Evenly, meaning the removal does not create new irregularity on your face. Precisely, meaning the raised area is mapped out fully beforehand, the way the material is pushed around by your expressions is accounted for, and once the swelling is gone we remove no more and no less. It is closer to precision fat grafting run backwards. The difficulty lies in judgement, not in nerve.

Ultrasound guidance is what gives those three a chance of being true. You can only be precise about material whose plane, capsule and relationship to vessels and nerves you can see. The full account of how we do this is on the filler repair service page.

What the steroid route costs

The other option the insert names is steroid treatment. It does work. It settles an inflamed nodule, and in the short term patients feel the improvement.

The cost comes later. Some people develop fat atrophy around the injected spot, and the result is a depression sitting next to material that is still in place. The lump looks flatter and the face has a new problem, one that is harder to repair than the original lump was.

None of which means steroid has no place. In acute inflammation, with redness, warmth and tenderness, calming things down first is reasonable. The problem is treating it as the long-term plan: one round fails, so another, and after three or four the nodule has not moved while the skin has started to thin.

For why repeated injections hit a ceiling with collagen-stimulator lumps, the limits of 5-FU and injectable management sets that out more fully.

What placement outside the approved site changes

The approved insert keeps the indication narrow: this product is an injectable filler indicated for correction of the nasolabial folds. The dose has a ceiling too, no more than 0.7ml per side per session. And the warnings include a line the insert wrote about itself: the product must not be used outside the approved indication.

What comes through the door is often the whole face, the cheeks, the temples, sometimes under the eyes.

Part of the reason for that gap is inside the same document. The remarks column of its reconstitution table describes the larger dilutions as being for fine wrinkles and the face generally. That line reads easily as endorsement for full-face use. Instructions for diluting are not an expanded indication, and the two need to be kept apart.

So what does that give you, if the lump is already there? It does not change how the nodule is handled. It changes two practical things.

First, what to ask when you go back for answers: which plane, which exact site, how much in total. Those answers feed straight into planning an extraction.

Second, what to expect about difficulty. Thin-skinned areas and the nasolabial fold are not the same job. Around the eye the skin is thin, the vessels are dense and there is little room to work, and material placed shallow and scattered raises the demand on judgement. The insert carries its own warnings for these areas, noting that inadvertent intravascular injection may lead to consequences as serious as blindness, strongly advising against the orbital area and thin skin, and stating that the product is not to be injected into the lips.

It is also worth noting the groups the insert flags as unsuitable or unstudied: sites with acute or chronic skin disease, allergy to any component, a tendency to hypertrophic scarring and keloids, a history of herpes (which may recur), clotting or liver dysfunction, and pregnancy, breastfeeding and under-18s. If you fall into one of those and were injected anyway, that is worth raising at a follow-up.

"The clinic says this is normal" — when to get a second opinion

To be fair: a lot of the time the clinic is right. Early swelling, mild unevenness, an area still changing. Watching is a reasonable thing to advise.

These are the situations where a second opinion earns its keep.

The same answer three times over, with no change in the lump. "Let's watch it" is advice for a stage, not a plan for a year.

Being told the gap is too long for the injection to be the cause. With this product, that statement does not match its own approved insert.

Injection is the only option on offer, and after a few rounds new problems are appearing: the skin over the site thinning, a hollow forming.

Nobody has looked with ultrasound. That is the one I weigh most. Feeling and seeing are different acts, and deciding whether and how far to treat without an image is guesswork.

Getting a second opinion is not setting yourself against your original doctor. More often than not, coming back with imaging makes it easier for them to give you a next step.

When waiting stops being reasonable

The most common question in clinic, and the one with the least tidy answer. Four things I weigh.

Time. The lump has been there beyond three to six months, its shape is stable, its position fixed, with no trend towards getting smaller.

Attempts. The same method has been tried two or three times with no clear change. Repeated injections are not neutral for the tissue. Each one provokes it again.

Imaging. Ultrasound shows a defined capsule, or material clearly clumped together. Once a capsule forms, there is not much left for massage and drugs to do.

Life. You can feel it, you can see it, it moves when you smile, or you check the mirror every day to see whether it has grown. There is no objective measure for this one. It is still real.

The more of the four you meet, the less reason there is to keep waiting. Waiting is not a neutral choice: the collagen is still being provoked, the fibrosis is still building.

Key point: "Let's watch it" is sound advice early on. Later it often just moves the difficulty further down the road. By the time the fibrosis is thicker and wider, removing it evenly is harder, not easier.

Frequently Asked Questions

My lump appeared more than a year after the injection. Can it still be related?

It can. The approved insert for this product states that subcutaneous nodules may appear late, 1 to 14 months after injection and sometimes as late as two years. Time alone is not enough to rule out the connection, and an ultrasound is more reliable than reasoning from the calendar.

Can NeoFilera be dissolved?

No. Hyaluronidase (to be used only after an in-person medical assessment) works on hyaluronic acid and does nothing to PDLLA, nor to the collagen your body builds around the particles. Once a nodule has encapsulated, physical extraction is the practical route, which is also one of the routes the insert names.

Is NeoFilera a Korean product?

No. It holds a Taiwanese domestic-manufacture licence, 008439, where the character 製 marks domestic manufacture rather than import. Chief Biotech holds it and Shuo-Nuo Biotechnology manufactures it. The Korean MFDS database has no entry for the product. Some pages online list it in the import series, which is the wrong series.

If it is marketed as low risk for nodules, why did I get one?

Low risk describes a probability across a population, not a guarantee for a person. The outcome also depends on the plane it was placed in, how much went into one spot, the dilution, the tissue conditions at that site, and how strongly you personally respond with collagen. Product characteristics are one input among several.

I was injected across the whole face, but the approved indication is the nasolabial folds. What does that mean?

It means that was use outside the approved indication, which is a decision your injector made, and a fair question to put to them. For the repair side, what it mainly changes is the planning: material spread thin across several areas behaves differently from a single depot.

Will removal leave a scar?

We work through ultrasound-guided micro-extraction, so the access point is small and in most cases it is inconspicuous once healed. But the wound is only one part of it. What decides how the face looks afterwards is whether the removal was even. Taking material out cleanly and leaving irregularity behind is not a success from where the patient is standing.

Does it have to come out? Can I wait a bit longer?

Not necessarily. A small nodule that does not show and is not inflamed can reasonably be watched. The more of the four criteria above you meet, the weaker the case for waiting. This depends on your situation and on how much it bothers you, and it is a decision to make with your doctor rather than a blanket "wait" or "operate".

If you want to know where you stand

If you have had NeoFilera or another collagen stimulator and you can now feel a lump, or one area keeps swelling, the first step is simple: find a doctor who images fillers with ultrasound and get the plane, the extent and the presence of a capsule established.

With that in hand you can have a real conversation about what to do next, instead of cycling between "let's watch it" and "let's inject it again".

I have spent years on filler extraction and revision, and a good share of my clinic is people whose problem was already treated somewhere else with a result they were not happy with. To talk through your situation, start at book a consultation.

The mechanism and risks of collagen stimulators as a class are set out separately in how collagen stimulators work and what they risk.